Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
STRO-004 · 1 trial · 9 indications
Best response of Complete Response (CR) or Partial Response (PR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST V1.1)
The proportion of participants with best response of CR, PR or Stable Disease (SD) per RECIST V1.1
Time from first occurrence of objective response to the time of Progressive Disease (PD) according to RECIST v1.1 or death from any cause, whichever comes first
Time from first dose to the first occurrence of PD according to RECIST v1.1 or death from any cause, whichever comes first
Percentage of participants alive 12 months after first dose of study treatment
| Arm | Type | Description |
|---|---|---|
| Part 1A STRO-004 Monotherapy | EXPERIMENTAL | - |
| Part 1B STRO-004 Monotherapy | EXPERIMENTAL | - |
| Part 1C STRO-004 in Combination with Pembrolizumab | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| STRO-004 | DRUG | IV Infusion |
| Pembrolizumab | DRUG | IV Infusion |
Inclusion Criteria: * Histologically or cytologically documented metastatic or locally advanced solid tumors including: Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Esophageal/Gastric Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Cervical Cancer, Endometrial Can...
STRO-004 is an investigational small molecule being developed for the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). It is also being studied in other advanced solid tumors including non-small cell lung cancer, esophageal, gastric, colorectal, pancreatic, cervical, endometrial, and urothelial cancers. The drug is currently in Phase 1 clinical development.
STRO-004 is being developed by Sutro Biopharma, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol STRO. The company is conducting clinical trials of STRO-004 in the United States.
STRO-004 is currently in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. A Phase 1 study is actively recruiting participants to evaluate the drug in adults with refractory or recurrent metastatic cancer.
STRO-004 is being evaluated in a single Phase 1 clinical trial with the identifier NCT07227168. The study is titled 'A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer' and is currently recruiting participants in the United States. The trial aims to enroll approximately 200 patients.
STRO-004 is a small molecule therapeutic agent. The specific molecular target of STRO-004 has not been disclosed in the available information. The drug is being investigated for its potential anti-cancer activity in multiple solid tumor types.